persons with schizophrenia in a number of settings. Data are needed to
profile geographical variation of this phenomenon, and to document
associations with local HIV context.
Methods: Naturalistic observational study using Medicaid Analytic
Extract (MAX) for 1999-2000 from California, Florida, New Jersey,
Texas, and New York. Cities selected were those >2000 Medicaid
beneficiaries. Diagnostic classification based on ICD-9-CM, one
inpatient or two outpatient claims. Eligibility criteria: Patients
aged 18-64 with claims for SZ (and a minimum of one full year
eligibility, no comprehensive HMO coverage and no long term care days.
Estimates of HIV/AIDS prevalence among injection drug users based on
Friedman, et al. (2005).
Results: In 110 selected cities, the treated HIV prevalence rate among
patients diagnosed with schizophrenia ranged from 0.0% to 8.3%, with a
median of 1.0%. For 34 of these cities, published rates of HIV among
injection drug users were available. Correlation between these rates
was 0.73.
Conclusions: In these administrative data, prior estimates of elevated
HIV among patients with schizophrenia do not provide a reliable guide to
infection rates across multiple geographic locations. The impact of HIV
on people with serious mental illness is likely to vary based on local
epidemic dynamics.
Learning Objectives:
Recognize wide variability in treated prevalence rates among patients with schizophrenia
Consider role of local epidemic conditions influencing these prevalence rates
Keywords: HIV/AIDS, Sever Mental Illness
Qualified on the content I am responsible for because: involved in conceptualization, interpretation, writingJa
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
![[ Visit Client Website ]](images/banner.gif)